Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy

Experimental Neurology

Volumn 234, Issue 2, 2012, Pages 405-416

  Ubhi, Kiren ^a   Inglis, Chandra ^a   Mante, Michael ^a   Patrick, Christina ^a   Adame, Anthony ^a   Spencer, Brian ^a   Rockenstein, Edward ^a   May, Verena ^c   Winkler, Juergen ^a,c   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Alpha synuclein; Antidepressant; Multiple System Atrophy; Parkinson's disease; Prozac

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN 1; SEROTONIN; UNCLASSIFIED DRUG;

ALPHA SYNUCLEINOPATHY; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BEHAVIOR DISORDER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DRUG ACTIVITY; HIPPOCAMPUS; MOTOR DYSFUNCTION; MOUSE; NEOCORTEX; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SEROTONINERGIC SYSTEM; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WHITE MATTER;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; FLUOXETINE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MICE; MICE, TRANSGENIC; MOTOR SKILLS; NERVE DEGENERATION; NEURONS; SEROTONIN UPTAKE INHIBITORS;

EID: 84858157780     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.01.008     Document Type: Article

References (81)

1. Abdel-Razaq W., Kendall D.A., Bates T.E. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem. Res. 2011, 36:327-338.
2. Aboukhatwa M., Dosanjh L., Luo Y. Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol. Neurodegener. 2010, 5:10.
3. Allaman I., Fiumelli H., Magistretti P.J., Martin J.L. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl). 2011, 216(1):75-84.
4. Arima K., Ueda K., Sunohara N., Arakawa K., Hirai S., Nakamura M., Tonozuka-Uehara H., Kawai M. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol. 1998, 96:439-444.
5. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
6. Chang E.A., Beyhan Z., Yoo M.S., Siripattarapravat K., Ko T., Lookingland K.J., Madhukar B.V., Cibelli J.B. Increased cellular turnover in response to fluoxetine in neuronal precursors derived from human embryonic stem cells. Int. J. Dev. Biol. 2010, 54:707-715.
7. Chung E.S., Chung Y.C., Bok E., Baik H.H., Park E.S., Park J.Y., Yoon S.H., Jin B.K. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res. 2010, 1363:143-150.
8. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J. Immunol. 2010, 185:1230-1237.
9. Chung Y.C., Kim S.R., Park J.Y., Chung E.S., Park K.W., Won S.Y., Bok E., Jin M., Park E.S., Yoon S.H., Ko H.W., Kim Y.S., Jin B.K. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011, 60:963-974.
10. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 2006, 200:256-261.
11. Crews L., Mizuno H., Desplats P., Rockenstein E., Adame A., Patrick C., Winner B., Winkler J., Masliah E. Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J. Neurosci. 2008, 28:4250-4260.
12. Djalali S., Holtje M., Grosse G., Rothe T., Stroh T., Grosse J., Deng D.R., Hellweg R., Grantyn R., Hortnagl H., Ahnert-Hilger G. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. J. Neurochem. 2005, 92:616-627.
13. Dong H., Goico B., Martin M., Csernansky C.A., Bertchume A., Csernansky J.G. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 2004, 127:601-609.
14. Du Y., Dreyfus C.F. Oligodendrocytes as providers of growth factors. J. Neurosci. Res. 2002, 68:647-654.
15. Enciu A.M., Nicolescu M.I., Manole C.G., Muresanu D.F., Popescu L.M., Popescu B.O. Neuroregeneration in neurodegenerative disorders. BMC Neurol. 2011, 11:75.
16. Gonzalez-Pinto A., Mosquera F., Palomino A., Alberich S., Gutierrez A., Haidar K., Vega P., Barbeito S., Ortiz A., Matute C. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int. Clin. Psychopharmacol. 2010, 25:241-245.
17. Halliday G. Clinicopathological aspects of motor parkinsonism. Parkinsonism Relat. Disord. 2007, 13(Suppl. 3):S208-S210.
18. Heberlein A., Lenz B., Muschler M., Frieling H., Buechl R., Groschl M., Kornhuber J., Bleich S., Hillemacher T. BDNF plasma levels decrease during benzodiazepine withdrawal in patients suffering from comorbidity of depressive disorder and benzodiazepine dependence. Psychopharmacology (Berl) 2010, 209:213-215.
19. Hisaoka K., Nishida A., Koda T., Miyata M., Zensho H., Morinobu S., Ohta M., Yamawaki S. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J. Neurochem. 2001, 79:25-34.
20. Hoke A., Ho T., Crawford T.O., LeBel C., Hilt D., Griffin J.W. Glial cell line-derived neurotrophic factor alters axon schwann cell units and promotes myelination in unmyelinated nerve fibers. J. Neurosci. 2003, 23:561-567.
21. Hong M., Mukhida K., Mendez I. GDNF therapy for Parkinson's disease. Expert Rev. Neurother. 2008, 8:1125-1139.
22. Hu X., Zhou H., Zhang D., Yang S., Qian L., Wu H.M., Chen P.S., Wilson B., Gao H.M., Lu R.B., Hong J.S. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. Neuroimmune Pharmacol. 2011, 10.1007/s11481-011-9309-0, PMID: 21870076.
23. Hunsberger J., Austin D.R., Henter I.D., Chen G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin. Neurosci. 2009, 11:333-348.
24. Ishido M. Melatonin inhibits maneb-induced aggregation of alpha-synuclein in rat pheochromocytoma cells. J. Pineal Res. 2007, 42:125-130.
25. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Spooren W., Fuss B., Mallon B., Macklin W.B., Fujiwara H., Hasegawa M., Iwatsubo T., Kretzschmar H.A., Haass C. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002, 3:583-588.
26. Klongpanichapak S., Phansuwan-Pujito P., Ebadi M., Govitrapong P. Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity. J. Pineal Res. 2007, 43:65-73.
27. Klongpanichapak S., Phansuwan-Pujito P., Ebadi M., Govitrapong P. Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells. Neurosci. Lett. 2008, 436:309-313.
28. Kubera M., Kenis G., Bosmans E., Kajta M., Basta-Kaim A., Scharpe S., Budziszewska B., Maes M. Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol. 2004, 4:185-192.
29. Lantos P.L., Papp M.I. Cellular pathology of multiple system atrophy: a review. J. Neurol. Neurosurg. Psychiatry 1994, 57:129-133.
30. Lauterbach E.C., Victoroff J., Coburn K.L., Shillcutt S.D., Doonan S.M., Mendez M.F. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J. Neuropsychiatry Clin. Neurosci. 2010, 22:8-18.
31. Lee C.S., Kim Y.J., Jang E.R., Kim W., Myung S.C. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin. Pharmacol. Toxicol. 2010, 106:446-453.
32. Lee A.H., Lange C., Ricken R., Hellweg R., Lang U.E. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J. Clin. Psychopharmacol. 2011, 31:334-336.
33. Leng Y., Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 2006, 26:7502-7512.
34. Li B., Zhang S., Zhang H., Nu W., Cai L., Hertz L., Peng L. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) 2008, 201:443-458.
35. Li B., Zhang S., Li M., Hertz L., Peng L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology (Berl) 2009, 207:1-12.
36. Li W.L., Cai H.H., Wang B., Chen L., Zhou Q.G., Luo C.X., Liu N., Ding X.S., Zhu D.Y. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J. Neurosci. Res. 2009, 87:112-122.
37. Li B., Zhang S., Li M., Hertz L., Peng L. Serotonin increases ERK1/2 phosphorylation in astrocytes by stimulation of 5-HT2B and 5-HT2C receptors. Neurochem. Int. 2010, 57:432-439.
38. Louis J.C., Magal E., Muir D., Manthorpe M., Varon S. CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J. Neurosci. Res. 1992, 31:193-204.
39. Machado-Vieira R., Manji H.K., Zarate C.A. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009, 11(Suppl. 2):92-109.
40. Marcussen A.B., Flagstad P., Kristjansen P.E., Johansen F.F., Englund U. Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol. Scand. 2008, 117:94-100.
41. Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov. Disord. 2003, 18(Suppl. 6):S21-S27.
42. Marxreiter F., Nuber S., Kandasamy M., Klucken J., Aigner R., Burgmayer R., Couillard-Despres S., Riess O., Winkler J., Winner B. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur. J. Neurosci. 2009, 29:879-890.
43. Mercier G., Lennon A.M., Renouf B., Dessouroux A., Ramauge M., Courtin F., Pierre M. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J. Mol. Neurosci. 2004, 24:207-216.
44. Nishimura T., Ishima T., Iyo M., Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008, 3:e2558.
45. Notterpek L. Neurotrophins in myelination: a new role for a puzzling receptor. Trends Neurosci. 2003, 26:232-234.
46. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., Lozano A.M., Penn R.D., Simpson R.K., Stacy M., Wooten G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
47. Parikh V., Terry A.V., Khan M.M., Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology (Berl) 2004, 172:365-374.
48. Perera T.D., Dwork A.J., Keegan K.A., Thirumangalakudi L., Lipira C.M., Joyce N., Lange C., Higley J.D., Rosoklija G., Hen R., Sackeim H.A., Coplan J.D. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One 2011, 6:e17600.
49. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
50. Quiroz J.A., Machado-Vieira R., Zarate C.A., Manji H.K. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010, 62:50-60.
51. Ramaswamy S., Soderstrom K.E., Kordower J.H. Trophic factors therapy in Parkinson's disease. Prog. Brain Res. 2009, 175:201-216.
52. Rantamaki T., Vesa L., Antila H., Di Lieto A., Tammela P., Schmitt A., Lesch K.P., Rios M., Castren E. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PLoS One 2011, 6:e20567.
53. Roumestan C., Michel A., Bichon F., Portet K., Detoc M., Henriquet C., Jaffuel D., Mathieu M. Anti-inflammatory properties of desipramine and fluoxetine. Respir. Res. 2007, 8:35.
54. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors P., Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003, 23:349-357.
55. Saragovi H.U., Hamel E., Di Polo A. A neurotrophic rationale for the therapy of neurodegenerative disorders. Curr. Alzheimer Res. 2009, 6(5):419-423.
56. Schaar D.G., Sieber B.A., Dreyfus C.F., Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp. Neurol. 1993, 124:368-371.
57. Shults C.W., Rockenstein E., Crews L., Adame A., Mante M., Larrea G., Hashimoto M., Song D., Iwatsubo T., Tsuboi K., Masliah E. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 2005, 25:10689-10699.
58. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev. 2000, 33:199-227.
59. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T., Masliah E. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 2009, 29:13578-13588.
60. Suzuki K., Okada K., Wakuda T., Shinmura C., Kameno Y., Iwata K., Takahashi T., Suda S., Matsuzaki H., Iwata Y., Hashimoto K., Mori N. Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine. PLoS One 2010, 5:e9260.
61. Tada M., Kakita A., Toyoshima Y., Onodera O., Ozawa T., Morita T., Nishizawa M., Takahashi H. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain 2009, 132:1810-1819.
62. Tolwani R.J., Cosgaya J.M., Varma S., Jacob R., Kuo L.E., Shooter E.M. BDNF overexpression produces a long-term increase in myelin formation in the peripheral nervous system. J. Neurosci. Res. 2004, 77:662-669.
63. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44:415-422.
64. Ubhi K., Rockenstein E., Mante M., Inglis C., Adame A., Patrick C., Whitney K., Masliah E. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J. Neurosci. 2010, 30:6236-6246.
65. Wakabayashi K., Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology 2006, 26:338-345.
66. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M., Takahashi H. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 1998, 96:445-452.
67. Wakabayashi K., Yoshimoto M., Tsuji S., Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 1998, 249:180-182.
68. Wang Y., Neumann M., Hansen K., Hong S.M., Kim S., Noble-Haeusslein L.J., Liu J. Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury. J. Neurotrauma 2011, 28:259-268.
69. Wilkins A., Majed H., Layfield R., Compston A., Chandran S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J. Neurosci. 2003, 23:4967-4974.
70. Winner B., Lie D.C., Rockenstein E., Aigner R., Aigner L., Masliah E., Kuhn H.G., Winkler J. Human wild-type alpha-synuclein impairs neurogenesis. J. Neuropathol. Exp. Neurol. 2004, 63:1155-1166.
71. Winner B., Rockenstein E., Lie D.C., Aigner R., Mante M., Bogdahn U., Couillard-Despres S., Masliah E., Winkler J. Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol. Aging 2008, 29:913-925.
72. Winner B., Kohl Z., Gage F.H. Neurodegenerative disease and adult neurogenesis. Eur. J. Neurosci. 2011, 33:1139-1151.
73. Winner B., Kohl Z., Gage F.H. Neurodegenerative disease and adult neurogenesis. Eur. J. Neurosci. 2011, 33:1139-1151.
74. Wyneken U., Sandoval M., Sandoval S., Jorquera F., Gonzalez I., Vargas F., Falcon R., Monari M., Orrego F. Clinically relevant doses of fluoxetine and reboxetine induce changes in the TrkB content of central excitatory synapses. Neuropsychopharmacology 2006, 31:2415-2423.
75. Xiao J., Wong A.W., Willingham M.M., Kaasinen S.K., Hendry I.A., Howitt J., Putz U., Barrett G.L., Kilpatrick T.J., Murray S.S. BDNF exerts contrasting effects on peripheral myelination of NGF-dependent and BDNF-dependent DRG neurons. J. Neurosci. 2009, 29:4016-4022.
76. Xiao J., Wong A.W., Willingham M.M., van den Buuse M., Kilpatrick T.J., Murray S.S. Brain-derived neurotrophic factor promotes central nervous system myelination via a direct effect upon oligodendrocytes. Neurosignals 2010, 18:186-202.
77. Yasuhara T., Shingo T., Date I. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med. Okayama 2007, 61:51-56.
78. Yazawa I., Giasson B.I., Sasaki R., Zhang B., Joyce S., Uryu K., Trojanowski J.Q., Lee V.M. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45:847-859.
79. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007, 27:484-493.
80. Zhang L., Ma Z., Smith G.M., Wen X., Pressman Y., Wood P.M., Xu X.M. GDNF-enhanced axonal regeneration and myelination following spinal cord injury is mediated by primary effects on neurons. Glia 2009, 57:1178-1191.
81. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.